| 期刊簡介 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Recent Patents on Anti-Cancer Drug Discovery LetPub Score 5.1
50 ratings
Rate
Reputation 6.3 Influence 3.8 Speed 7.0 | ||||||||||||||||||||||||||||
| 期刊簡稱 | RECENT PAT ANTI-CANC | ||||||||||||||||||||||||||||
| ISSN | 1574-8928 | ||||||||||||||||||||||||||||
| E-ISSN | 2212-3970 | ||||||||||||||||||||||||||||
| h-index | 36 | ||||||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||||||
| 自引率 (2023-2024) | 4.00%自引率趨勢 | ||||||||||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||||||||||
| 官方網站 | http://www.recentpatentsonanticancerdrugdiscovery.com/ | ||||||||||||||||||||||||||||
| 在線稿件提交 | http://bsp-cms.eurekaselect.com/index.php/PRA/login?source=%2Findex.php%2FPRA | ||||||||||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||||||||||
| 出版商 | Bentham Science Publishers B.V. | ||||||||||||||||||||||||||||
| 主題領域 | 医学 | ||||||||||||||||||||||||||||
| 出版國/地區 | U ARAB EMIRATES | ||||||||||||||||||||||||||||
| 發行頻率 | 年3回刊行 | ||||||||||||||||||||||||||||
| 創刊年 | 2006 | ||||||||||||||||||||||||||||
| 每年文章數 | 38每年文章數趨勢 | ||||||||||||||||||||||||||||
| 黃金OA百分比 | 0.00% | ||||||||||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q3
| ||||||||||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1574-8928%5BISSN%5D | ||||||||||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: About 3.0 month(s) | ||||||||||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Recent Patents on Anti-Cancer Drug Discovery] 的評論 | 撰寫評論 |
| 作者: 罗汉子骞 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2024-03-25 16:15:20 評論於 Is there a requirement to provide a brief introduction of each author?  (0) 讚！ | 罗汉子骞  |
| 作者: 回风念南 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2024-01-23 11:59:04 評論於 Please explain the review process, senior (0) 讚！ | 回风念南 |
| 作者: 残月东霞 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2024-01-19 17:59:06 評論於 Review speed: 3.0 | Submission acceptance rate: 50.0 Research focus: Anti-tumor experience sharing | Publication fee: $580 (0) 讚！ | 残月东霞 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 18:48:34 評論於 The list of SCI journal rankings of the Chinese Academy of Sciences is still an essential reference directory for research performance rewards and title evaluations for many universities and research institutions in China (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 龙鳞孝礼 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-29 15:09:58 評論於 There are many journal classifications, how to choose the right journal? (0) 讚！ | 龙鳞孝礼 |
| 作者: 修然小公主 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-26 11:37:52 評論於 Is it necessary to consider zoning when selecting publications? (0) 讚！ | 修然小公主 |
| 作者: Jason Chen 領域: 医学 審稿時間: 2.0 month(s) 結果: 直接被接受 撰寫評論 |
2021-01-17 06:11:28 評論於 We recently wrote and submitted an article reviewing natural products for cancer treatment. After making a few minor revisions, it was accepted. I was informed that they also accept case reports. (4) 讚！ | Jason Chen |
| 作者: 东京千霜 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2020-05-04 23:49:32 評論於 Review speed: 1.0 Experience sharing: I would like to let you guys know that the new editor-in-chief is not from Pakistan, instead, he is a Chinese in USA. Welcome to submit articles to this journal! (0) 讚！ | 东京千霜 |
| 作者: Hyman Jefferson 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2020-05-04 13:36:58 評論於 Review Speed: 1.0 Experience Sharing: I had submitted two papers to this journal, and each time, it takes about one month for the review process (0) 讚！ | Hyman Jefferson |
| 作者: Jason Chen 領域: 医学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2020-05-04 05:20:06 評論於 I would like to let you guys know that the new editor-in-chief is not from Pakistan, instead, he is a Chinese in USA. Welcome to submit articles to this journal! (2) 讚！ | Jason Chen |
| 作者: Jason Chen 領域: 医学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2020-05-04 00:27:14 評論於 I had submitted two papers to this journal, and each time, it takes about one month for review process. (0) 讚！ | Jason Chen |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-07-18 16:32:17 評論於 The past was good, but now it's so frightening to see it fall so low. I want to get back to a 3-point level next year, but it might be really difficult (0) 讚！ | 凌霄高洁 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2012-11-28 10:54:46 評論於 Can we reach 3 points next year? Let's discuss (0) 讚！ | 凌霄高洁 |
| 作者: 匿名 領域: 抗癌药物制剂 審稿時間: 0.0 month(s) 結果: 撰寫評論 |
2011-03-06 19:32:00 評論於 At the time, our research team received a letter of invitation from the journal. The editor of the journal is very responsible, the editor will send you some related patents for your reference. In addition, I submitted in mid-January 2009, and I received a revised opinion in mid-March, indicating that it can be published after minor repairs. (1) 讚！ | 匿名 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
